Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Dipyridamole modulated Tc-99m sestamibi lung SPECT in small cell lung cancer
Autore:
Bom, HS; Lim, SC; Kim, YC; Song, HC; Min, JJ; Jeong, HJ; Kim, JY; Lee, J; Park, KO;
Indirizzi:
Chonnam Univ Hosp, Dept Nucl Med, Kwangju 501757, South Korea Chonnam UnivHosp Kwangju South Korea 501757 Kwangju 501757, South Korea Chonnam Univ Hosp, Dept Internal Med, Kwangju 501757, South Korea Chonnam Univ Hosp Kwangju South Korea 501757 Kwangju 501757, South Korea Kyungpook Univ Hosp, Dept Nucl Med, Taegu, South Korea Kyungpook Univ Hosp Taegu South Korea Dept Nucl Med, Taegu, South Korea
Titolo Testata:
CLINICAL NUCLEAR MEDICINE
fascicolo: 2, volume: 24, anno: 1999,
pagine: 97 - 101
SICI:
0363-9762(199902)24:2<97:DMTSLS>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; PHASE-I; ADENOSINE UPTAKE; ETOPOSIDE; ENHANCEMENT; SENSITIVITY; INHIBITION; ADRIAMYCIN; VERAPAMIL;
Keywords:
Tc-99m sestamibi; dipyridamole; small cell lung cancer; P-glycoprotein;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Bom, HS Chonnam Univ Hosp, Dept Nucl Med, 8 Hakdong, Kwangju 501757, SouthKorea Chonnam Univ Hosp 8 Hakdong Kwangju South Korea 501757 outh Korea
Citazione:
H.S. Bom et al., "Dipyridamole modulated Tc-99m sestamibi lung SPECT in small cell lung cancer", CLIN NUCL M, 24(2), 1999, pp. 97-101

Abstract

Purpose: In this study, the authors wanted to determine whether dipyridamole-modulated MIBI (dipyridamole-MIBI) could enhance the prediction of the response to chemotherapy in patients with small cell lung cancer. Methods: Twenty-seven patients with biopsy-proved small cell lung cancer (25 men, 2 women; mean age, 61+/-7 years) underwent dipyridamole-MIBI SPECT 3 to 7 days before starting chemotherapy (80 mg/m(2) etoposide and 80 mg/m(2) cisplatin every 3 or 4 weeks for at least two cycles), Tomographic images before and after dipyridamole (0.84 mg/kg) were acquired 1 hour after injection of 370 (10 mCi) and 1,110 (30 mCi) MBq MIBI, respectively, The response to chemotherapy was grouped as specified as complete response (CR), partial (PR), no change (NC), or progressive disease (PD), according to the change in tumor size on chest roentgenography and CT. Patients showing CR andPR were classified as responders, and those who showed NC and PD were considered nonresponders. Results: Among the 27 patients, 22 were responders (3 CR, 19 PR) and 5 were nonresponders (3 NC, 2 PD), The tumor-to-normal lung ratio (T:NL) of responders was significantly higher than that of nonresponders. The diagnostic accuracy of the T:NL ratio to differentiate responders and nonresponders was 33.3%, with a cutoff value of 2.5, which was significantly improved to 77.8% when an increased T:NL ratio after dipyridamole was assigned to a nonresponder. Furthermore, all patients with CR showed diminished T:NL ratios after dipyridamole, and all patients with NR showed an increased T:NL ratio after dipyridamole,Conclusion: Dipyridamole-MIBI SPECT could enhance the prediction of response to chemotherapy in patients with small cell lung cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 06:35:11